Email Alert | RSS

北京大学学报（医学版） ›› 2026, Vol. 58 ›› Issue (2): 423-430. doi: 10.19723/j.issn.1671-167X.2026.02.031

• 综述 • 上一篇    下一篇

恶性肿瘤中蛋白质乳酸化修饰的研究进展

董海峰, 陈恒星, 张常华*()   

  1. 中山大学附属第七医院消化医学中心，广东省消化系统恶性肿瘤防治研究重点实验室，广东深圳 518000
  • 收稿日期:2025-12-01 出版日期:2026-04-18 发布日期:2026-02-06
  • 通讯作者: 张常华
  • 基金资助:
    国家自然科学基金(82573049); 广东省基础与应用基础研究基金(2025B1515020095); 深圳市“医疗卫生三名工程”资助项目(SZSM202411013); 深圳市“医疗卫生三名工程”资助项目(SZSM202411023); 深圳市基础研究资助项目(JCYJ20240813150212017); 深圳市消化系统疾病(消化外科)临床医学研究中心资助项目(LCYSSQ20220823091203008); 中山大学附属第七医院科研启动经费(ZSQYRSSFAR0008)

Research progress on protein lactylation modification in malignant tumors

Haifeng DONG, Hengxing CHEN, Changhua ZHANG*()   

  1. Digestive Disease Center, The Seventh Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Digestive Cancer Research, Shenzhen 518000, Guangdong, China
  • Received:2025-12-01 Online:2026-04-18 Published:2026-02-06
  • Contact: Changhua ZHANG
  • Supported by:
    the National Natural Science Foundation of China(82573049); The Guangdong Basic and Applied Basic Research Foundation(2025B1515020095); The Sanming Project of Medicine in Shenzhen(SZSM202411013); The Sanming Project of Medicine in Shenzhen(SZSM202411023); The Shenzhen Fundamental Research Program(JCYJ20240813150212017); The Shenzhen Clinical Research Center for Gastroenterology (Gastrointestinal Surgery)(LCYSSQ20220823091203008); The Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University(ZSQYRSSFAR0008)

RICH HTML

   

PDF (PC)

摘要：

恶性肿瘤是一类以异常增殖和侵袭性生长为特征的疾病，严重威胁人类健康。肿瘤细胞普遍存在瓦博格效应(Warburg effect)，即在有氧条件下仍进行高速糖酵解，产生大量乳酸。乳酸传统上被视为代谢废物，近年研究发现其不仅是重要的代谢物，更可作为信号分子，通过新型蛋白质翻译后修饰——乳酸化修饰，在基因表达和细胞功能调控中发挥核心作用。组蛋白乳酸化修饰的发现，揭示了细胞代谢状态与表观遗传调控间直接相连的全新机制。随后的蛋白质组学研究证实，乳酸化修饰广泛存在于各类非组蛋白中，成为一种重要的调控方式。乳酸化修饰是由写入酶催化、消除酶去除的动态可逆过程。在恶性肿瘤中，乳酸化修饰通过作用于组蛋白和非组蛋白两大类底物，广泛参与肿瘤的发生发展，在表观遗传层面，组蛋白乳酸化重塑染色质状态，重编程基因表达；在功能层面，非组蛋白乳酸化直接调控信号通路关键蛋白、代谢酶和DNA修复因子的活性，二者协同驱动肿瘤免疫微环境重塑、转移扩散、治疗抵抗及代谢异常等核心恶性表型。本文系统综述了乳酸化修饰的发现历程、分子机制，并重点阐述了其在肿瘤代谢、免疫及治疗抵抗中的最新研究进展。同时，探讨了针对乳酸化修饰的潜在治疗策略，包括调控乳酸代谢、干预修饰酶系统，以及开发特异性阻断工具。尽管该领域在酶的特异性和功能研究方面仍面临挑战，但针对乳酸化修饰的深入研究，为理解肿瘤代谢-表观遗传交叉对话提供了全新视角，并为开发创新的肿瘤诊断与治疗策略奠定了理论基础。

关键词: 乳酸化修饰, 肿瘤, 乳酸, 蛋白质翻译后修饰, 表观遗传

Abstract:

Malignant tumors, a class of diseases characterized by abnormal proliferation and aggressive growth, pose a severe threat to human health. A hallmark of tumor cell biology is the pervasive presence of the Warburg effect, wherein cells undergo high-rate glycolysis leading to substantial lactate production, even under aerobic conditions. Traditionally regarded merely as a metabolic waste product, lactate has been re-evaluated through recent research, which reveals it to be not only a crucial metabolite but also a significant signaling molecule. It exerts core regulatory functions in gene expression and cellular activity through a novel post-translational modification: Protein lactylation. The seminal discovery of histone lactylation unveiled a direct and novel mechanistic link between cellular metabolic states and epigenetic regulation. Subsequent proteomic studies have substantiated that lactylation is a widespread modification existing across various types of non-histone proteins, establishing it as an important regulatory mechanism. The process of lactylation modification is dynamic and reversible, orchestrated by specific "writer" enzymes that catalyze its addition and "eraser" enzymes that facilitate its removal. Within the context of malignant tumors, lactylation modification participates extensively in tumorigenesis and progression by targeting two primary classes of substrate proteins: Histones and non-histone proteins. At the epigenetic level, histone lactylation remodels chromatin state and reprograms gene expression profiles. At the functional level, lactylation of non-histone proteins directly modulates the activity of key signaling pathway components, metabolic enzymes, and DNA repair factors. The synergistic action of these two facets collectively drives core malignant phenotypes, including remodeling of the tumor immune microenvironment, facilitation of metastasis and dissemination, induction of therapy resistance, and dysregulation of metabolism. This review provides a systematic overview of the discovery, molecular mechanisms, and recent advances concerning the roles of lactylation in tumor metabolism, immunity, and treatment resistance. It further explores potential therapeutic strategies targeting lactylation, such as modulating lactate metabolism, intervening in the enzymatic machinery of the modification system, and developing specific blocking agents. Although challenges remain regarding the specificity of the involved enzymes and the functional validation of these modifications, in-depth research on lactylation offers a fresh perspective for understanding the crosstalk between tumor metabolism and epigenetics. It also lays a theoretical foundation for the development of innovative strategies for cancer diagnosis and therapy.

Key words: Lactylation, Tumor, Lactate, Post-translational modification, Epigenetic

中图分类号: 

  • R730.2

图1

蛋白质乳酸化修饰的发生机制及其在恶性肿瘤中的核心功能示意图"

1
Brooks GA , Osmond AD , Arevalo JA , et al. Lactate as a myokine and exerkine: Drivers and signals of physiology and metabolism[J]. J Appl Physiol, 2023, 134 (3): 529- 548.

doi: 10.1152/japplphysiol.00497.2022
2
Certo M , Llibre A , Lee W , et al. Understanding lactate sensing and signalling[J]. Trends Endocrinol Metab, 2022, 33 (10): 722- 735.

doi: 10.1016/j.tem.2022.07.004
3
Li X , Yang Y , Zhang B , et al. Lactate metabolism in human health and disease[J]. Signal Transduct Target Ther, 2022, 7 (1): 305.

doi: 10.1038/s41392-022-01151-3
4
Brooks GA . Lactate as a fulcrum of metabolism[J]. Redox Biol, 2020, 35, 101454.

doi: 10.1016/j.redox.2020.101454
5
Hou X , Hong Z , Zeng H , et al. Lactylation in cancer biology: Unlocking new avenues for research and therapy[J]. Cancer Commun, 2025, 45 (11): 1367- 1406.

doi: 10.1002/cac2.70054
6
Wishart DS . Is cancer a genetic disease or a metabolic disease?[J]. EBioMedicine, 2015, 2 (6): 478- 479.

doi: 10.1016/j.ebiom.2015.05.022
7
Racker E . Bioenergetics and the Problem of Tumor Growth: An understanding of the mechanism of the generation and control of biological energy may shed light on the problem of tumor growth[J]. Am Sci, 1972, 60 (1): 56- 63.
8
de la Cruz-López KG , Castro-Muñoz LJ , Reyes-Hernández DO , et al. Lactate in the regulation of tumor microenvironment and therapeutic approaches[J]. Front Oncol, 2019, 9, 1143.

doi: 10.3389/fonc.2019.01143
9
Zhang D , Tang Z , Huang H , et al. Metabolic regulation of gene expression by histone lactylation[J]. Nature, 2019, 574 (7779): 575- 580.

doi: 10.1038/s41586-019-1678-1
10
Sun L , Zhang H , Gao P . Metabolic reprogramming and epigenetic modifications on the path to cancer[J]. Protein Cell, 2022, 13 (12): 877- 919.

doi: 10.1007/s13238-021-00846-7
11
Yao W , Hu X , Wang X . Crossing epigenetic frontiers: The intersection of novel histone modifications and diseases[J]. Signal Transduct Target Ther, 2024, 9 (1): 232.

doi: 10.1038/s41392-024-01918-w
12
Li Y , Zhang R , Hei H . Advances in post-translational modifications of proteins and cancer immunotherapy[J]. Front Immunol, 2023, 14, 1229397.

doi: 10.3389/fimmu.2023.1229397
13
Xu H , Wu M , Ma X , et al. Function and mechanism of novel histone posttranslational modifications in health and disease[J]. Biomed Res Int, 2021, 2021, 6635225.

doi: 10.1155/2021/6635225
14
Fu Y , Yu J , Li F , et al. Oncometabolites drive tumorigenesis by enhancing protein acylation: From chromosomal remodelling to nonhistone modification[J]. J Exp Clin Cancer Res, 2022, 41 (1): 144.

doi: 10.1186/s13046-022-02338-w
15
Wan N , Wang N , Yu S , et al. Cyclic immonium ion of lactyl-lysine reveals widespread lactylation in the human proteome[J]. Nat Meth, 2022, 19 (7): 854- 864.

doi: 10.1038/s41592-022-01523-1
16
Yang YH , Wang QC , Kong J , et al. Global profiling of lysine lactylation in human lungs[J]. Proteomics, 2023, 23 (15): e2200437.

doi: 10.1002/pmic.202200437
17
Wu X . In-depth discovery of protein lactylation in hepatocellular carcinoma[J]. Proteomics, 2023, 23 (9): e2300003.

doi: 10.1002/pmic.202300003
18
Hong H , Chen X , Wang H , et al. Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinoma[J]. Proteomics, 2023, 23 (9): e2200432.

doi: 10.1002/pmic.202200432
19
Lin J , Liu G , Chen L , et al. Targeting lactate-related cell cycle activities for cancer therapy[J]. Semin Cancer Biol, 2022, 86 (Pt 3): 1231- 1243.
20
Yang D , Yin J , Shan L , et al. Identification of lysine-lactylated substrates in gastric cancer cells[J]. iScience, 2022, 25 (7): 104630.

doi: 10.1016/j.isci.2022.104630
21
Jiang P , Ning W , Shi Y , et al. FSL-Kla: A few-shot learning-based multi-feature hybrid system for lactylation site prediction[J]. Comput Struct Biotechnol J, 2021, 19, 4497- 4509.

doi: 10.1016/j.csbj.2021.08.013
22
Liberti MV , Locasale JW . Histone lactylation: A new role for glucose metabolism[J]. Trends Biochem Sci, 2020, 45 (3): 179- 182.

doi: 10.1016/j.tibs.2019.12.004
23
Wang P , Xie D , Xiao T , et al. H3K18 lactylation promotes the progression of arsenite-related idiopathic pulmonary fibrosis via YTHDF1/m6A/NREP[J]. J Hazard Mater, 2024, 461, 132582.

doi: 10.1016/j.jhazmat.2023.132582
24
Li L , Chen K , Wang T , et al. Glis1 facilitates induction of pluripotency via an epigenome-metabolome-epigenome signalling cascade[J]. Nat Metab, 2020, 2 (9): 882- 892.

doi: 10.1038/s42255-020-0267-9
25
Kozlakidis Z , Shi P , Abarbanel G , et al. Recent developments in protein lactylation in PTSD and CVD: Novel strategies and targets[J]. BioTech, 2023, 12 (2): 38.

doi: 10.3390/biotech12020038
26
Li R , Yang Y , Wang H , et al. Lactate and lactylation in the brain: Current progress and perspectives[J]. Cell Mol Neurobiol, 2023, 43 (6): 2541- 2555.

doi: 10.1007/s10571-023-01335-7
27
Zong Z , Xie F , Wang S , et al. Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis[J]. Cell, 2024, 187 (10): 2375- 2392.e33.

doi: 10.1016/j.cell.2024.04.002
28
Chen H , Li Y , Li H , et al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance[J]. Nature, 2024, 631 (8021): 663- 669.

doi: 10.1038/s41586-024-07620-9
29
Chen Y , Wu J , Zhai L , et al. Metabolic regulation of homologous recombination repair by MRE11 lactylation[J]. Cell, 2024, 187 (2): 294- 311.

doi: 10.1016/j.cell.2023.11.022
30
Ali I , Conrad RJ , Verdin E , et al. Lysine acetylation goes global: From epigenetics to metabolism and therapeutics[J]. Chem Rev, 2018, 118 (3): 1216- 1252.

doi: 10.1021/acs.chemrev.7b00181
31
Moreno-Yruela C , Zhang D , Wei W , et al. Class Ⅰ histone deacetylases (HDAC1-3) are histone lysine delactylases[J]. Sci Adv, 2022, 8 (3): eabi6696.

doi: 10.1126/sciadv.abi6696
32
Walenta S , Wetterling M , Lehrke M , et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers[J]. Cancer Res, 2000, 60 (4): 916- 921.
33
Ewaschuk JB , Naylor JM , Zello GA . D-lactate in human and ruminant metabolism[J]. J Nutr, 2005, 135 (7): 1619- 1625.

doi: 10.1093/jn/135.7.1619
34
Varner EL , Trefely S , Bartee D , et al. Quantification of lactoyl-CoA (lactyl-CoA) by liquid chromatography mass spectrometry in mammalian cells and tissues[J]. Open Biol, 2020, 10 (9): 200187.

doi: 10.1098/rsob.200187
35
Gaffney DO , Jennings EQ , Anderson CC , et al. Non-enzymatic lysine lactoylation of glycolytic enzymes[J]. Cell Chem Biol, 2020, 27 (2): 206- 213.

doi: 10.1016/j.chembiol.2019.11.005
36
Yang T , Zhang S , Nie K , et al. ZNF207-driven PRDX1 lactylation and NRF2 activation in regorafenib resistance and ferroptosis evasion[J]. Drug Resist Updat, 2025, 82, 101274.

doi: 10.1016/j.drup.2025.101274
37
Liu R , Wu J , Guo H , et al. Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets[J]. MedComm, 2023, 4 (3): e292.

doi: 10.1002/mco2.292
38
Huang ZW , Zhang XN , Zhang L , et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immuno-suppression in acute myeloid leukemia[J]. Signal Transduct Target Ther, 2023, 8 (1): 391.

doi: 10.1038/s41392-023-01605-2
39
De Leo A , Ugolini A , Yu X , et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma[J]. Immunity, 2024, 57 (5): 1105- 1123.

doi: 10.1016/j.immuni.2024.04.006
40
Sun T , Liu B , Li Y , et al. Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation[J]. J Exp Clin Cancer Res, 2023, 42 (1): 253.

doi: 10.1186/s13046-023-02815-w
41
Gu J , Zhou J , Chen Q , et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells[J]. Cell Rep, 2022, 40 (3): 111122.

doi: 10.1016/j.celrep.2022.111122
42
Yang J , Yu X , Xiao M , et al. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer[J]. Gut, 2025, 74 (11): e334361.
43
Wang J , Liu Z , Xu Y , et al. Enterobacterial LPS-inducible LINC00152 is regulated by histone lactylation and promotes cancer cells invasion and migration[J]. Front Cell Infect Microbiol, 2022, 12, 913815.

doi: 10.3389/fcimb.2022.913815
44
Zhou J , Xu W , Wu Y , et al. GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway[J]. Oncogene, 2023, 42 (45): 3319- 3330.

doi: 10.1038/s41388-023-02841-0
45
Li X , Zhang C , Mei Y , et al. Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair[J]. Signal Transduct Target Ther, 2025, 10 (1): 214.

doi: 10.1038/s41392-025-02302-y
46
Li F , Si W , Xia L , et al. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma[J]. Mol Cancer, 2024, 23 (1): 90.

doi: 10.1186/s12943-024-02008-9
47
Chen M , Cen K , Song Y , et al. NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma[J]. Cancer Lett, 2023, 567, 216285.

doi: 10.1016/j.canlet.2023.216285
48
Miao Z , Zhao X , Liu X . Hypoxia induced β-catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the Wnt signaling pathway[J]. Exp Cell Res, 2023, 422 (1): 113439.

doi: 10.1016/j.yexcr.2022.113439
49
Jin J , Bai L , Wang D , et al. SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth[J]. EMBO Rep, 2023, 24 (5): e56052.

doi: 10.15252/embr.202256052
50
Pandkar MR , Sinha S , Samaiya A , et al. Oncometabolite lactate enhances breast cancer progression by orchestrating histone lactylation-dependent c-Myc expression[J]. Transl Oncol, 2023, 37, 101758.

doi: 10.1016/j.tranon.2023.101758
51
Wu H , Wang Y , Ying M , et al. Lactate dehydrogenases amplify reactive oxygen species in cancer cells in response to oxidative stimuli[J]. Signal Transduct Target Ther, 2021, 6 (1): 242.

doi: 10.1038/s41392-021-00595-3
52
Maeda M , Ko M , Mane MM , et al. Genetic and drug inhibition of LDH-A: Effects on murine gliomas[J]. Cancers, 2022, 14 (9): 2306.

doi: 10.3390/cancers14092306
53
Zhang W , Wang C , Hu X , et al. Inhibition of LDHA suppresses cell proliferation and increases mitochondrial apoptosis via the JNK signaling pathway in cervical cancer cells[J]. Oncol Rep, 2022, 47 (4): 77.

doi: 10.3892/or.2022.8288
54
Jin L , Chun J , Pan C , et al. Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis[J]. Oncogene, 2017, 36 (27): 3797- 3806.

doi: 10.1038/onc.2017.6
55
Qiao T , Xiong Y , Feng Y , et al. Inhibition of LDHA by oxamate enhances the efficacy of anti-PD-1 treatment in an NSCLC humanized mouse model[J]. Front Oncol, 2021, 11, 632364.

doi: 10.3389/fonc.2021.632364
56
Elia I , Rossi M , Stegen S , et al. Breast cancer cells rely on environmental pyruvate to shape the metastatic niche[J]. Nature, 2019, 568 (7750): 117- 121.

doi: 10.1038/s41586-019-0977-x
57
McNeillis R , Greystoke A , Walton J , et al. A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965[J]. Br J Cancer, 2020, 122 (8): 1141- 1145.

doi: 10.1038/s41416-020-0727-8
58
He ZX , Wei BF , Zhang X , et al. Current development of CBP/p300 inhibitors in the last decade[J]. Eur J Med Chem, 2021, 209, 112861.

doi: 10.1016/j.ejmech.2020.112861
59
Kaufman JL , Mina R , Jakubowiak AJ , et al. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: Results of a Multiple Myeloma Research Consortium Phase Ⅰ Study[J]. Blood Cancer J, 2019, 9 (1): 3.

doi: 10.1038/s41408-018-0154-8
60
Ogura M , Ando K , Suzuki T , et al. A multicentre phase Ⅱ study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma[J]. Br J Haematol, 2014, 165 (6): 768- 776.

doi: 10.1111/bjh.12819
61
O'Connor OA , Horwitz S , Masszi T , et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase Ⅱ BELIEF (CLN-19) study[J]. J Clin Oncol, 2015, 33 (23): 2492- 2499.

doi: 10.1200/JCO.2014.59.2782
62
Zinzani PL , Pellegrini C , Cerciello G , et al. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program[J]. Leuk Lymphoma, 2016, 57 (10): 2370- 2374.

doi: 10.3109/10428194.2015.1137292
63
Wang C , Feng F , Pan L , et al. Reply to the letter titled: Demethylzeylasteral targets lactate to suppress the tumorigenicity of liver cancer stem cells: Is it attributed to histone lactylation?[J]. Pharmacol Res, 2023, 194, 106868.

doi: 10.1016/j.phrs.2023.106868
64
Jia M , Yue X , Sun W , et al. ULK1-mediated metabolic reprogramming regulates Vps34 lipid kinase activity by its lactylation[J]. Sci Adv, 2023, 9 (22): eadg4993.

doi: 10.1126/sciadv.adg4993
[1] 季加孚, 韦静涛, 季科, 步召德. 胃癌诊疗的瓶颈与破局：迈向精准化与智能化融合的新纪元[J]. 北京大学学报（医学版）, 2026, 58(2): 231-238.
[2] 高加勒, 张忠涛. 局部进展期直肠癌精准治疗现状与展望[J]. 北京大学学报（医学版）, 2026, 58(2): 247-250.
[3] 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 251-256.
[4] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报（医学版）, 2026, 58(2): 257-265.
[5] 杜文, 章文博, 于尧, 刘硕, 苏惠裕, 胡耒豪, 唐祖南, 吴彬彰, 陈震, 李家琦, 王昊, 彭歆. 口腔颌面部肿瘤"数智化外科"诊疗流程探索与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 278-284.
[6] 王楠楠, 袁大晋, 朱昱冰, 丁磊. 结直肠癌根治术后肝转移风险多中心列线图预测模型的构建与验证[J]. 北京大学学报（医学版）, 2026, 58(2): 290-300.
[7] 刘友东, 吕亚军, 陈杰, 臧明德, 潘宏达, 刘晓文, 陆俊, 刘凤林. 全腹腔镜保留贲门胃底胃次全切除术治疗中上部胃癌的疗效及安全性[J]. 北京大学学报（医学版）, 2026, 58(2): 301-306.
[8] 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报（医学版）, 2026, 58(2): 399-404.
[9] 李斌, 梁寒. 机器人胃癌根治术：研究进展与实践挑战[J]. 北京大学学报（医学版）, 2026, 58(2): 416-422.
[10] 李宏杨, 黄涛, 王琳琳. 脂肪肌肉比率与卵巢良性肿瘤风险的关联性[J]. 北京大学学报（医学版）, 2026, 58(1): 169-174.
[11] 高若凡, 马天宇, 王润楷, 殷雨辰, 李芮迪, 王丹丹, 夏斌. 细胞膜囊泡递送靶向肿瘤坏死因子-α的小干扰RNA对牙髓干细胞的抗炎作用[J]. 北京大学学报（医学版）, 2026, 58(1): 22-29.
[12] 刘艳华, 陆敏, 赵旭阳, 张宽根, 武睿, 梅放, 戴志豪, 由江峰, 裴斐. 肿瘤转移抑制基因LASS2去磷酸化对液泡型ATP酶活性及前列腺癌侵袭性的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1113-1123.
[13] 杨小勇, 张帆, 马潞林, 刘承. 前列腺导管腺癌临床特征及腺外侵犯的影响因素[J]. 北京大学学报（医学版）, 2025, 57(5): 956-960.
[14] 陈定一, 杜浩鑫, 张逸晨, 王闫飞, 刘巍, 焦园园, 史录文, 管晓东, 卢新璞. 姑息治疗对晚期癌症患者药物使用和医疗资源利用的影响[J]. 北京大学学报（医学版）, 2025, 57(5): 996-1001.
[15] 宁家昕, 王浩然, 罗书航, 敬吉波, 王建业, 侯惠民, 刘明. 氧化应激相关基因与前列腺癌关系的多组学分析[J]. 北京大学学报（医学版）, 2025, 57(4): 633-643.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部